JG
ALNY icon

Joel Greenblatt’s Alnylam Pharmaceuticals ALNY Stock Holding History

Joel Greenblatt’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7M Sell
42,051
-1,659
-4% -$500K 0.03% 742
2026
Q1 		$14.5M Buy
43,710
+4,088
+10% +$1.39M 0.04% 573
2025
Q4 		$15.8M Buy
39,622
+11,487
+41% +$5.08M 0.06% 484
2025
Q3 		$12.8M Buy
28,135
+10,348
+58% +$4.21M 0.06% 491
2025
Q2 		$5.8M Buy
17,787
+3,270
+23% +$905K 0.03% 621
2025
Q1 		$3.92M Buy
14,517
+3,593
+33% +$923K 0.03% 597
2024
Q4 		$2.57M Sell
10,924
-6,651
-38% -$1.75M 0.02% 660
2024
Q3 		$4.83M Buy
17,575
+4,338
+33% +$1.13M 0.05% 500
2024
Q2 		$3.22M Buy
13,237
+11,190
+547% +$1.77M 0.04% 553
2024
Q1 		$306K Sell
2,047
-8,762
-81% -$1.46M ﹤0.01% 1178
2023
Q4 		$2.07M Buy
10,809
+7,727
+251% +$1.32M 0.04% 592
2023
Q3 		$546K Sell
3,082
-775
-20% -$148K 0.01% 950
2023
Q2 		$733K Sell
3,857
-1,259
-25% -$250K 0.02% 858
2023
Q1 		$1.02M Buy
5,116
+1,730
+51% +$364K 0.02% 736
2022
Q4 		$805K Buy
3,386
+3
+0.1% +$640 0.02% 754
2022
Q3 		$677K Buy
3,383
+277
+9% +$52.8K 0.02% 771
2022
Q2 		$453K Buy
3,106
+1,808
+139% +$256K 0.01% 813
2022
Q1 		$212K Buy
+1,298
New +$198K 0.01% 1065
2020
Q2 		– Sell
-4,464
Closed -$486K – 1054
2020
Q1 		$486K Buy
4,464
+1,544
+53% +$178K 0.01% 726
2019
Q4 		$336K Buy
+2,920
New +$291K 0.01% 912
2017
Q4 		– Sell
-2,499
Closed -$294K – 926
2017
Q3 		$294K Sell
2,499
-7,185
-74% -$613K ﹤0.01% 805
2017
Q2 		$772K Buy
+9,684
New +$619K 0.01% 679

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Joel Greenblatt's ALNY Position: Q2 2026 in Review

Joel Greenblatt reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.8% in Q2 2026, selling an estimated $500K and leaving 42,051 shares worth $12.7M. The position accounts for 0.03% of the portfolio, ranked #742.

Joel Greenblatt first reported a position in ALNY in Q2 2017 and has held it in 22 quarters since. The position peaked at $15.8M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Joel Greenblatt held 42,051 shares of Alnylam Pharmaceuticals worth $12.7M as of Q2 2026.
  • Joel Greenblatt sold 1,659 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $500K.
  • Alnylam Pharmaceuticals made up 0.03% of Joel Greenblatt's portfolio in Q2 2026, its #742 holding.
  • Joel Greenblatt first reported a position in Alnylam Pharmaceuticals in Q2 2017 and has held it in 22 quarters since.
  • Joel Greenblatt's Alnylam Pharmaceuticals position peaked at $15.8M in Q4 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.